CLCong Li

Cong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cong Li has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Binyi Xiao

    Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China

    1 shared publication
  • De-Sen Wan

    Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

    1 shared publication
  • Fulong Wang

    Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA

    1 shared publication
  • Gong Chen

    Sun Yat-sen University Cancer Center 1 Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, China

    1 shared publication
  • Hengji Huang

    Department of Neurosurgery, Dongguan People′s Hospital, Dongguan, Guangdong Province, China, dgtpyy.com

    1 shared publication
  • Huan Tian

    Department of Radiology, Aerospace Center Hospital, No. 15, Yuquan Road, Haidian District, Beijing 100049, China

    1 shared publication

Latest Publications

  • Open Access

    Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide‐Resistant Glioblastoma

    by Weixuan Chen, Cong Li, Yun Liu, Hengji Huang

    Background: Glioblastoma (GBM) is the most prevalent primary brain tumor. Despite extensive investigations, GBM′s resistance to the first‐line drug temozolomide (TMZ) remains a major challenge in clinical management. This study explores the molecular mechanisms underlying TMZ resistance in GBM, emphasizing the roles of DNA repair gene polymorphisms and intratumoral genetic heterogeneity. Methods: In this study, we collected 10 matched pairs of GBM surgical samples, including tumor tissues from the first and second surgeries, and proceeded with RNA‐Seq and Exome‐Seq. We performed pathway enrichment analysis and functional assays for key genetic variations in the DNA repair pathway to establish a mechanistic relationship between genetic changes and drug resistance. Sanger sequencing validated somatic variations before and after chemotherapy, and we analyzed changes in gene expression associated with DNA repair. The methylation status of the promoter region of the MGMT gene was analyzed, in addition to the effect of DNA repair genes on TMZ sensitivity in cells. Results: This study identified 20 novel somatic mutations that uniquely occurred in pre‐TMZ and post‐TMZ chemotherapy samples and were significantly related to DNA repair pathways (including base excision repair [BER] and nucleotide excision repair [NER]). Functional validation experiments confirmed that the alterations in the expressed variants had disrupted important repair mechanisms related to the survival of tumor cells. Notably, differential dysregulation of the NER and BER pathways (upregulated NER and inactivated BER) was observed in recurrent tumors, serving as a compensatory mechanism for TMZ resistance. Methylation of the MGMT gene promoter region has been linked to TMZ resistance, while intratumoral genetic heterogeneity might increase the chance of resistance. Importantly, our observations point toward an evolutionary event following TMZ treatment that incorporates selective pressures for repair‐deficient clones, resulting in a more aggressive fate for GBM. Cellular studies showed that the proliferation and migration ability of U87 cells were significantly elevated after the knockdown of XAB2, PNKP, and OGG1. Conclusion: This study represents the first comprehensive characterization of TMZ resistance in GBM based on integrated genetic, epigenetic, and functional validation approaches. In GBM, mechanisms of TMZ resistance are elucidated, with the interplay between the NER and BER pathways (compensatory regulation) being a key mechanism, alongside variations in DNA repair genes and intratumoral genetic heterogeneity. These findings highlight the importance of targeting the crosstalk between NER and BER pathways for GBM therapy, emphasizing the necessity of personalized treatment strategies and suggesting possible biomarkers for patient stratification by resistance profiles. Overall, these findings provide new avenues for developing personalized treatment strategies for GBM and can contribute to improving the prognosis of GBM patients.


  • Open Access

    An early report of a screening program for colorectal cancer in Guangzhou, China

    by Yujing Fang, Binyi Xiao, Jianhong Peng, Huan Tian, Fulong Wang, Lingheng Kong, Shiyong Lin, Jibin Li, Qiying Su, Kunwu Luo, et al.

    Background: We launched a screening program for colorectal cancer (CRC) in Yuexiu District, Guangzhou, China, in 2014. Here we aimed to report the early results of the program and evaluate the benefits of a screening questionnaire. Methods: Residents aged between 50 and 74 were eligible for the screening. A questionnaire and two consecutive fecal immunological tests (FITs) were used as primary screening methods. Subjects who were positive for any of the two tests were referred for further examination with colonoscopy. Neoplasms were removed either colonoscopically or by colectomy. Atypical adenoma and CRC were defined as advanced neoplasms. Results: A total of 6,971 residents in Dadong Street, Yuexiu District were screened with a questionnaire, and among them, 5,343 underwent at least one FIT. Four thousand and two hundred eleven (60.4%) were female, and 2,760 (39.6%) were male, with a median age of 62.0 years. Questionnaire and FITs identified 1,219 candidates for further examination with colonoscopy, among whom only 647 (53.1%) comply. As of this writing, 623 colonoscopy results were obtained, among which 270 (43.3%) had positive findings. The adenoma detection rate (ADR) was 43.3% (270/623). The ADR was 43.3% (270/623). Of the 270 patients, 10 (3.07%) had CRC, 81 (30.0%) had advanced adenoma, 178 had low-grade adenoma or other benign polyps, one had carcinoid. Except for three advanced CRC, all neoplasms detected were benign or in an early stage. Conclusions: Our screening program help identified patients with colonic neoplasms at an early stage, precluding them from developing into the malignant disease. The addition of the questionnaire significantly increased the sensitivity of primary screening, while also decreasing the specificity. Long-term results should evaluate the social and economic benefits of this program.